KR101506348B1 - Ｃｈ5ｄ 항체로부터의 탈면역된 길항적 항-인간 ｃｄ40 모노클로날 항체 - Google Patents

Ｃｈ5ｄ 항체로부터의 탈면역된 길항적 항-인간 ｃｄ40 모노클로날 항체 Download PDF

Info

Publication number
KR101506348B1
KR101506348B1 KR1020087030080A KR20087030080A KR101506348B1 KR 101506348 B1 KR101506348 B1 KR 101506348B1 KR 1020087030080 A KR1020087030080 A KR 1020087030080A KR 20087030080 A KR20087030080 A KR 20087030080A KR 101506348 B1 KR101506348 B1 KR 101506348B1
Authority
KR
South Korea
Prior art keywords
ser
gly
thr
leu
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020087030080A
Other languages
English (en)
Korean (ko)
Other versions
KR20090029203A (ko
Inventor
마르셀 데오도러스 덴 할토그
루프레크트 줄리스 주스트 반 네어벤
케빈 스튜어트 죤슨
로버트 둔칸 케슨
Original Assignee
패스트 포워드 파머슈티컬스 비.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 패스트 포워드 파머슈티컬스 비.브이. filed Critical 패스트 포워드 파머슈티컬스 비.브이.
Publication of KR20090029203A publication Critical patent/KR20090029203A/ko
Application granted granted Critical
Publication of KR101506348B1 publication Critical patent/KR101506348B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020087030080A 2006-05-09 2007-05-09 Ｃｈ5ｄ 항체로부터의 탈면역된 길항적 항-인간 ｃｄ40 모노클로날 항체 Active KR101506348B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US79881906P 2006-05-09 2006-05-09
US60/798,819 2006-05-09
EP06076028.7 2006-05-09
EP06076028A EP1854810A1 (en) 2006-05-09 2006-05-09 Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
PCT/NL2007/050202 WO2007129895A2 (en) 2006-05-09 2007-05-09 Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody

Publications (2)

Publication Number Publication Date
KR20090029203A KR20090029203A (ko) 2009-03-20
KR101506348B1 true KR101506348B1 (ko) 2015-04-08

Family

ID=37635851

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087030080A Active KR101506348B1 (ko) 2006-05-09 2007-05-09 Ｃｈ5ｄ 항체로부터의 탈면역된 길항적 항-인간 ｃｄ40 모노클로날 항체

Country Status (20)

Country Link
US (1) US8669352B2 (enExample)
EP (2) EP1854810A1 (enExample)
JP (1) JP5179474B2 (enExample)
KR (1) KR101506348B1 (enExample)
CN (1) CN101490086B (enExample)
AR (1) AR060998A1 (enExample)
AU (1) AU2007249031B9 (enExample)
BR (1) BRPI0711355A2 (enExample)
CA (1) CA2651565A1 (enExample)
CL (1) CL2007001335A1 (enExample)
DK (1) DK2019840T3 (enExample)
ES (1) ES2406163T3 (enExample)
IL (1) IL195196A (enExample)
MX (1) MX2008014304A (enExample)
NO (1) NO20085104L (enExample)
NZ (1) NZ572756A (enExample)
RU (1) RU2491295C2 (enExample)
TW (1) TWI455947B (enExample)
WO (1) WO2007129895A2 (enExample)
ZA (2) ZA200810381B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5250548B2 (ja) 2006-06-21 2013-07-31 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 疾患の治療のための補体ｈ因子の標的化
ME01699B (me) 2009-07-02 2014-09-20 Musc Found For Res Dev Metode za stimulaciju regeneracije jetre
SI2462158T1 (en) 2009-08-06 2018-04-30 F. Hoffmann-La Roche Ag Method to improve virus removal in protein purification
MX2012005151A (es) 2009-11-05 2012-08-23 Federico Ii University Of Naples Tratamiento de hemoglobinuria nocturna paroxismica, anemias hemoliticas y estados de enfermedad que involucran hemolisis intravascular y extravascular.
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
AU2011235214B2 (en) * 2010-03-31 2015-04-23 Boehringer Ingelheim International Gmbh Anti-CD40 antibodies
JP5986990B2 (ja) 2010-05-14 2016-09-06 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレート 改善された補体レセプター２（ｃｒ２）ターゲティング基
SG186397A1 (en) 2010-06-22 2013-01-30 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
PL2683406T3 (pl) 2011-03-11 2019-11-29 Beth Israel Deaconess Medical Ct Inc Przeciwciała anty-cd40 i ich zastosowania
PL2699601T3 (pl) 2011-04-21 2018-05-30 Bristol-Myers Squibb Company Polipeptydy przeciwciała, które antagonizują CD40
SMT202000091T1 (it) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
CN105636984A (zh) * 2013-06-13 2016-06-01 法斯特弗沃德制药有限公司 用于治疗慢性炎症和预防胃肠道癌或纤维化的cd40信号转导抑制剂和其他化合物，该其他化合物是胆汁酸、胆汁酸衍生物、tgr5受体激动剂、fxr激动剂或其组合
EP2883883A1 (en) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
EP3113796A1 (en) 2014-03-07 2017-01-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
HUE054148T2 (hu) * 2014-08-07 2021-08-30 Daiichi Sankyo Co Ltd Anti-ORAI1 antitest
WO2016028810A1 (en) * 2014-08-18 2016-02-25 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
US9888673B2 (en) 2014-12-10 2018-02-13 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
HUE048284T2 (hu) 2015-05-29 2020-07-28 Abbvie Inc Anti-CD40 antitestek és alkalmazásuk
BR112018004296B1 (pt) 2015-09-04 2020-05-05 Primatope Therapeutics Inc anticorpos anti-cd40 humanizados e usos dos mesmos
CN108368510B (zh) 2015-09-30 2023-09-01 詹森生物科技公司 特异性结合人cd40的激动性抗体和使用方法
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
CA3055433A1 (en) * 2017-03-29 2018-10-04 Glycotope Gmbh Humanized anti-cd40 antibodies
CN110267989B (zh) 2017-06-01 2023-04-04 江苏恒瑞医药股份有限公司 抗cd40抗体、其抗原结合片段及其医药用途
KR20200074993A (ko) 2017-11-03 2020-06-25 노파르티스 아게 쇼그렌 증후군 치료에 사용하기 위한 항-cd40 항체
EP3752532A1 (en) * 2018-02-12 2020-12-23 Diabetes-Free, Inc. Improved antagonistic anti-human cd40 monoclonal antibodies
BR112020020277A2 (pt) 2018-04-13 2021-01-19 Novartis Ag Anticorpos anti-cd40 para uso na prevenção de rejeição de enxerto
AU2019255781A1 (en) * 2018-04-20 2020-10-29 Lyvgen Biopharma Holdings Limited Anti-CD40 antibodies and uses thereof
CN112638375A (zh) 2018-06-15 2021-04-09 旗舰创业创新五公司 通过后细胞信号传导因子的调节来增加免疫活性
CN116063495A (zh) 2018-09-28 2023-05-05 礼进生物医药科技（上海）有限公司 具有经过工程化的Fc结构域的抗CD40结合分子及其治疗用途
WO2020070288A1 (en) 2018-10-05 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and systems for controlling the agonistic properties of antibody variable domains by light
WO2020102454A1 (en) 2018-11-13 2020-05-22 Regents Of The University Of Minnesota Cd40 targeted peptides and uses thereof
BR112021010414A2 (pt) 2018-11-30 2021-09-08 Jiangsu Hengrui Medicine Co., Ltd. Composição farmacêutica compreendendo um anticorpo cd40, método para preparar uma preparação liofilizada, preparação liofilizada, uso das mesmas e produto que compreende um recipiente contendo as mesmas
CN112969714B (zh) 2018-11-30 2022-11-22 江苏恒瑞医药股份有限公司 抗cd40抗体、其抗原结合片段及其医药用途
MX2021008305A (es) 2019-01-11 2021-08-24 Novartis Ag Anticuerpos anti-cd40 para el uso en el tratamiento de hidradenitis supurativa.
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
CN113784985A (zh) 2019-05-08 2021-12-10 诺华股份有限公司 T1dm和胰岛炎的治疗中使用的抗cd40抗体
JP2022553493A (ja) 2019-09-11 2022-12-23 ノバルティス アーゲー 患者におけるヒトウイルス関連障害を予防するための方法
WO2021127217A1 (en) 2019-12-17 2021-06-24 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
EP4172323A1 (en) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
HRP20250696T1 (hr) 2021-01-28 2025-08-01 Regeneron Pharmaceuticals, Inc. Sastavi i postupci za liječenje sindroma oslobađanja citokina
KR20230165276A (ko) 2021-03-31 2023-12-05 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션 폴리펩티드 및 암의 치료에서의 이의 용도
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2023020475A1 (en) * 2021-08-16 2023-02-23 Utc Therapeutics (Shanghai) Co., Ltd. Cd40-targetting antibodies and uses thereof
EP4393937A1 (en) 2021-08-26 2024-07-03 Duality Biologics (Suzhou) Co., Ltd. Steroid compound and conjugate thereof
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
WO2023198851A1 (en) 2022-04-14 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for controlling the tumor cell killing by light
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
US20250277048A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998052976A1 (en) * 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
EP0651797B1 (en) 1992-07-09 2004-01-28 Chiron Corporation A method for generation of antibodies to cell surface molecules
EP0922111B1 (en) 1996-07-23 2004-12-01 Tanox Pharma B.V. Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998052976A1 (en) * 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
elementary pharmacology & therapeutics. 2005, Vol.22, No. 2, pp.111-122 *

Also Published As

Publication number Publication date
KR20090029203A (ko) 2009-03-20
CN101490086B (zh) 2014-03-05
ZA200810381B (en) 2010-03-31
HK1131627A1 (en) 2010-01-29
AU2007249031B9 (en) 2013-01-24
IL195196A (en) 2016-02-29
WO2007129895A2 (en) 2007-11-15
ZA200909185B (en) 2012-07-25
TWI455947B (zh) 2014-10-11
IL195196A0 (en) 2011-08-01
US8669352B2 (en) 2014-03-11
CA2651565A1 (en) 2007-11-15
NO20085104L (no) 2009-02-09
EP2019840A2 (en) 2009-02-04
BRPI0711355A2 (pt) 2011-09-27
MX2008014304A (es) 2008-11-26
AU2007249031B2 (en) 2012-09-27
ES2406163T3 (es) 2013-06-05
RU2491295C2 (ru) 2013-08-27
CN101490086A (zh) 2009-07-22
WO2007129895A3 (en) 2008-12-31
US20080085531A1 (en) 2008-04-10
TW200815471A (en) 2008-04-01
EP2019840B1 (en) 2012-12-19
JP2009536522A (ja) 2009-10-15
NZ572756A (en) 2012-10-26
DK2019840T3 (da) 2013-03-25
EP1854810A1 (en) 2007-11-14
AR060998A1 (es) 2008-07-30
RU2008148303A (ru) 2010-06-20
WO2007129895A9 (en) 2009-02-19
JP5179474B2 (ja) 2013-04-10
CL2007001335A1 (es) 2008-01-18
AU2007249031A1 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
KR101506348B1 (ko) Ｃｈ5ｄ 항체로부터의 탈면역된 길항적 항-인간 ｃｄ40 모노클로날 항체
JP5478254B2 (ja) 抗ノッチ３アゴニスト抗体とノッチ３関連疾患の治療におけるその使用
US20230059094A1 (en) Improved antagonistic anti-human cd40 monoclonal antibodies
US20100136030A1 (en) Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
JP2015535820A (ja) Ｋｉｒ３ｄｌ２結合剤
CA2769464C (en) Humanized anti-amyloid-.beta. oligomer antibody
JP2021519594A (ja) 抗ｔｒｅｍ−１抗体およびその使用
IL297638A (en) Compounds and methods targeting interleukin-34
CN115087672A (zh) 抗人hvem(tnfrsf14)抗体及其用途
KR20240099435A (ko) 인간 종양 괴사 인자 알파 항체
JP6555687B2 (ja) 免疫制御剤
AU2019217207B2 (en) Improved antagonistic anti-human CD40 monoclonal antibodies
TW202521577A (zh) 抗ｏｘ４０ｌ抗體以及其用途
CN120590530A (zh) 靶向tl1a的抗体及其应用
HK1131627B (zh) 来自ch5d12抗体的去免疫拮抗性抗人cd40单克隆抗体
CN114874323A (zh) 抗gitr抗体及其用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20081209

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120508

Comment text: Request for Examination of Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20130917

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20131028

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140620

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20131028

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20140718

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20140620

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20150226

Appeal identifier: 2014101004424

Request date: 20140718

AMND Amendment
PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20140806

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20140718

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20140328

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20120508

Patent event code: PB09011R02I

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140903

Patent event code: PE09021S01D

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20150226

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20140829

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20150320

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20150320

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20180308

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20180308

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20190307

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20190307

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20200312

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20210708

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20220311

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20230309

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20240913

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20250611

Start annual number: 11

End annual number: 11